FDA Warns Ferring, Says Firmagon Sales Pitch Is Misleading

Law360, Washington (April 13, 2012, 6:01 PM EDT) -- Ferring Pharmaceuticals Inc. was hit with a warning letter from the U.S. Food and Drug Administration, posted to the agency's website Friday, for making unsubstantiated claims that its prostate cancer treatment could be used as an early-stage therapy.

The letter focused on an electronic Ferring sales aid for Firmagon, which is approved to treat advanced prostate cancer. The iPad sales aid misbranded Firmagon as a preradiation, or neoadjuvant, treatment and a potential therapy for elevated prostate specific antigen, or PSA, according to the FDA.

But clinical...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.